Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study.

Xiaoyan Lin,Jin Li,Shukui Qin,Lu Wen,Junsheng Wang,Wenying Deng,Tongfu Jia,Yi Ba,Haijun Zhong,Jianwei. Yang,Yuxian Bai,Yifu He,Zhong Xie,Tienan Yi,Xiang Yuan Wu,Feng Ye,Likun Liu,Yong Huang,Mei Wang,Guifang Zhang

Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study.

2018

Xiaoyan Lin
Jin Li
Shukui Qin
Lu Wen
Junsheng Wang
Wenying Deng
Tongfu Jia
Yi Ba
Haijun Zhong
Jianwei. Yang
Yuxian Bai
Yifu He
Zhong Xie
Tienan Yi
Xiang Yuan Wu
Feng Ye
Likun Liu
Yong Huang
Mei Wang
Guifang Zhang

e16026Background: Apatinib, a small molecule VEGFR TKI, has been approved in the treatment of advanced gastric cancer in China. The real benefits of apatinib for different patients (pts) with ECOG ...

Keywords:

Physical therapy
Apatinib
Medicine
vegfr tki
Oncology
Internal medicine
Pathology
advanced gastric cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations